Published in Arch Intern Med on September 12, 1994
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Bone targeted treatments in cancer - The story so far. J Bone Oncol (2016) 0.75
Pamidronate for cancer-associated hypercalcemia. Arch Intern Med (1995) 0.75
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med (1996) 5.87
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism (2000) 2.69
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol (1998) 2.60
The unfolded protein response: an intracellular signalling pathway with many surprising features. Trends Cell Biol (1998) 2.48
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Chief complaint of fatigue: a prospective study. J Fam Pract (1990) 2.25
The "tamponade test" in the management of massive postpartum hemorrhage. Obstet Gynecol (2003) 2.25
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene (1997) 1.97
Early fixation of an optimal genetic code. Mol Biol Evol (2000) 1.94
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Cryptorchidism in cats. Vet Rec (2001) 1.93
The molecular basis of nuclear genetic code change in ciliates. Curr Biol (2001) 1.65
Academic stress, power motivation, and decrease in secretion rate of salivary secretory immunoglobulin A. Lancet (1983) 1.49
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol (1995) 1.48
Portable stove use is associated with lower lung cancer mortality risk in lifetime smoky coal users. Br J Cancer (2008) 1.47
Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc Natl Acad Sci U S A (1994) 1.43
Why patients consult and what happens when they do. BMJ (1991) 1.42
Types of patients in a psychiatric intensive care unit. Aust N Z J Psychiatry (2001) 1.42
Some factors associated with mortality in perforated peptic ulcer: a case-control study. J Gastroenterol Hepatol (1996) 1.42
Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release (1998) 1.41
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol (2002) 1.40
Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004. Transfus Med (2007) 1.40
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest (1997) 1.39
Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer. Cancer J Sci Am (2006) 1.38
Commercialism in marketing. Br Dent J (2006) 1.38
HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens (1999) 1.35
Activation of nuclear factor kappaB in single living cells. Dependence of nuclear translocation and anti-apoptotic function on EGFPRELA concentration. J Biol Chem (1999) 1.27
Lymphangiosarcoma. Cancer (1981) 1.26
NF-kappaB inhibits apoptosis in murine mammary epithelia. J Biol Chem (2000) 1.25
Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. Am J Med (1983) 1.24
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med (1993) 1.23
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol (2011) 1.23
The sensitivity and specificity of a modified ELISA for the diagnosis of Johne's disease from a field trial in cattle. Vet Microbiol (1990) 1.23
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
The multiple phosphorylation of the microtubule-associated protein MAP2 controls the MAP2:tubulin interaction. Eur J Biochem (1984) 1.22
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer (1984) 1.14
Collapse of the N=28 shell closure in (42)Si. Phys Rev Lett (2007) 1.13
Ulcerative colitis in association with Takayasu's disease. Am J Dig Dis (1978) 1.13
Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol (1999) 1.12
Near-infrared mass median particle size determination of lactose monohydrate, evaluating several chemometric approaches. Analyst (1998) 1.11
A randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate + magnesium citrate solution for bowel cleansing prior to colonoscopy. Curr Med Res Opin (2008) 1.10
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Thiol proteases released in vitro by Fasciola hepatica. Mol Biochem Parasitol (1989) 1.08
Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. Int J Radiat Oncol Biol Phys (2001) 1.06
Indwelling catheterization and related nursing practice. J Adv Nurs (1988) 1.05
Problems in attracting and retaining psychiatrists in rural areas. Hosp Community Psychiatry (1981) 1.05
The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys (2001) 1.05
The fate of the unoperated staghorn calculus. Br J Urol (1973) 1.02
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol (1997) 1.01
Origins of anteroposterior patterning and Hox gene regulation during chordate evolution. Philos Trans R Soc Lond B Biol Sci (2001) 1.01
Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage (1998) 1.00
Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol (1998) 1.00
Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat (2001) 0.99
Effects of ventilatory patterns on arterial oxygenation after near-drowning in sea water. Anesthesiology (1974) 0.99
Fasciola hepatica: a secreted cathepsin L-like proteinase cleaves host immunoglobulin. Int J Parasitol (1993) 0.99
Do proteins predate DNA? Science (1999) 0.99
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer (2006) 0.98
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol (1997) 0.98
Management of metastases-induced acute pancreatitis in small cell carcinoma of the lung. Cancer (1990) 0.97
Factors influencing adult learning within medicine. Aust Fam Physician (1977) 0.97
Chemotherapy of advanced, hormonally resistant prostatic carcinoma. Oncology (1980) 0.96
Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther (2004) 0.96
A photometric redshift of z = 6.39 +/- 0.12 for GRB 050904. Nature (2006) 0.96
Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecol Oncol (1991) 0.95
Replacement therapy for congenital Factor X deficiency. Transfusion (1985) 0.95
Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol (1997) 0.95
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res (1984) 0.95
Extracorporeal life support for adult cardiorespiratory failure. Surgery (1993) 0.94
Markers of bone resorption in patients treated with pamidronate. Eur J Cancer (1998) 0.94
Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol (2003) 0.94
Microbial hydroxylation of 1,4-cineole. Appl Environ Microbiol (1987) 0.93
Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology (2001) 0.93
A retrospective study of first indicators of breast cancer recurrence. Oncology (2000) 0.93
Renal insufficiency and volume overload in neonatal ECMO managed by continuous ultrafiltration. ASAIO Trans (1987) 0.93
Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut (1995) 0.92
Extracorporeal membrane oxygenation in term newborns. A prospective cost-benefit analysis. ASAIO J (1994) 0.92
Development of a risk index for the prediction of chronic post-surgical pain. Eur J Pain (2011) 0.91
Telomere length in myelodysplastic syndromes. Am J Hematol (1997) 0.91
Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). Cancer Treat Rep (1983) 0.91
Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study. J Surg Oncol (1996) 0.90
Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs (2001) 0.90
The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol (2001) 0.89
Cyclical combination chemotherapy and thyroid function in patients with advanced Hodgkin's disease. Med Pediatr Oncol (1981) 0.89